FDA Section 5 \u2022 cited verbatim

Bimatoprost - Warnings and Precautions

The following warnings and precautions are taken directly from the US FDA-approved drug label for Bimatoprost. This is the same information dispensing pharmacists read.

5 WARNINGS AND PRECAUTIONS • Concurrent administration of bimatoprost ophthalmic solution and intraocular pressure (IOP)-lowering prostaglandin analogs in ocular hypertensive patients may decrease the IOP-lowering effect.

Patients using these products concomitantly should be closely monitored for changes to their IOP. • Pigmentation of the eyelids and iris may occur.

Iris pigmentation is likely to be permanent. ( 5.2 , 5.3 ) 5.1 Effects on Intraocular Pressure Bimatoprost ophthalmic solution (Lumigan ® ) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP.

In clinical trials, in patients with or without elevated IOP, bimatoprost ophthalmic solution lowered IOP, however, the magnitude of the reduction was not cause for clinical concern.

In ocular hypertension studies with Lumigan ® , it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect.

In patients using Lumigan ® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of bimatoprost ophthalmic solution may interfere with the desired reduction in IOP.

Patients using prostaglandin analogs including Lumigan ® for IOP reduction should only use bimatoprost ophthalmic solution after consulting with their physician and should be monitored for changes to their intraocular pressure.

5.2 Iris Pigmentation Increased iris pigmentation has occurred when bimatoprost solution was administered.

Patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent [see Adverse Reactions ].

The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes.

The long term effects of increased pigmentation are not known.

Iris color changes seen with administration of bimatoprost ophthalmic solution may not be noticeable for several months to years.

Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish.

Neither nevi nor freckles of the iris appear to be affected by treatment.

Treatment with bimatoprost ophthalmic solution can be continued in patients who develop noticeably increased iris pigmentation.

5.3 Lid Pigmentation Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.

The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.

5.4 Hair Growth Outside the Treatment Area There is the potential for hair growth to occur in areas where bimatoprost ophthalmic solution comes in repeated contact with the skin surface.

It is important to apply bimatoprost ophthalmic solution only to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying sterile applicators, and to carefully blot any excess bimatoprost ophthalmic solution from the eyelid margin to avoid it running onto the cheek or other skin areas.

5.5 Intraocular Inflammation Bimatoprost ophthalmic solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

5.6 Macular Edema Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution (Lumigan ® ) for elevated IOP.

Bimatoprost ophthalmic solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

5.7 Contamination of Bimatoprost Ophthalmic Solution or Applicators The bimatoprost ophthalmic solution bottle must be kept intact during use.

It is important to use bimatoprost ophthalmic solution as instructed, by placing one drop on the single-use-per-eye applicator.

The bottle tip should not be allowed to contact any other surface since it could become contaminated.

Applies to YOU?

Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 29+ warnings apply to your profile.

Ask Health AI \u2192